Basit öğe kaydını göster

Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study

dc.contributor.authorJenkins, David P.
dc.contributor.authorJais, Xavier
dc.contributor.authorMartin, Nicolas
dc.contributor.authorMadani, Michael M.
dc.contributor.authorJing, Zhi-Cheng
dc.contributor.authorKim, Nick H.
dc.contributor.authorGhofrani, Hossein-Ardeschir
dc.contributor.authorSimonneau, Gerald
dc.contributor.authorD'Armini, Andrea M.
dc.contributor.authorFedullo, Peter
dc.contributor.authorHoward, Luke S.
dc.contributor.authorRichard, Dominik
dc.contributor.authorPapadakis, Kelly
dc.contributor.authorMayer, Eckhard
dc.date.accessioned2022-02-18T09:05:19Z
dc.date.available2022-02-18T09:05:19Z
dc.date.issued2017
dc.identifier.citationGhofrani H., Simonneau G., D'Armini A. M. , Fedullo P., Howard L. S. , Jais X., Jenkins D. P. , Jing Z., Madani M. M. , Martin N., et al., "Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study", LANCET RESPIRATORY MEDICINE, cilt.5, sa.10, ss.785-794, 2017
dc.identifier.issn2213-2600
dc.identifier.othervv_1032021
dc.identifier.otherav_17bd30c0-f450-44e9-ba90-6bb46f418ec3
dc.identifier.urihttp://hdl.handle.net/20.500.12627/176488
dc.identifier.urihttps://doi.org/10.1016/s2213-2600(17)30305-3
dc.description.abstractBackground Macitentan is beneficial for long-term treatment of pulmonary arterial hypertension. The microvasculopathy of chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension are similar.
dc.language.isoeng
dc.subjectPulmonary and Respiratory Medicine
dc.subjectSOLUNUM SİSTEMİ
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectGöğüs Hastalıkları ve Allerji
dc.subjectİç Hastalıkları
dc.subjectYoğun Bakım
dc.subjectCritical Care and Intensive Care Medicine
dc.subjectRespiratory Care
dc.subjectHealth Sciences
dc.subjectYOĞUN BAKIM
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.titleMacitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study
dc.typeMakale
dc.relation.journalLANCET RESPIRATORY MEDICINE
dc.contributor.departmentGerman Ctr Lung Res DZL , ,
dc.identifier.volume5
dc.identifier.issue10
dc.identifier.startpage785
dc.identifier.endpage794
dc.contributor.firstauthorID3385724


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster